Efficacy of S-1 or Capecitabine Plus Oxaliplatin Adjuvant Chemotherapy for Stage II or III Gastric Cancer after Curative Gastrectomy: A Systematic Review and Meta-Analysis.

Cancers (Basel) · 2022 · PMC9406447 · PMID 36010933

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

[ 15 ], a slight trend towards a better five-year DFS for S-1 was observed (HR =1.05, 95% CI 0.88–1.26).

also in 4,078 other papers

showed a trendno p-value reported

[ 16 ], S-1 chemotherapy showed a trend toward a better five-year DFS in stage II (HR 1.85, 95% CI 0.69–4.92); however, there was no difference in the five-year DFS between the two regimens in stage III (HR 0.94, 95% CI 0.66–1.34).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.